Nomura/Instinet analyst, Christopher Marai, reiterated his Buy rating on shares of Biogen (NASDAQ: BiIB) after the company reported 1Q18 results ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE